New York, USA (CU)_ Accutar Biotechnology, Inc., a biotechnology firm specialized in AI-enabled medication discovery, reported that the first patient in a Phase 1 study of AC0682, which is an orally bioavailable, chimeric degrader molecule specifically designed to target and degrade ER protein with high potency and selectivity, has received their dose.
Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc., expressed hopes over the new treatment. He said, “The initiation of this study represents a significant milestone for Accutar, as it marks the first program from our AI-enabled drug discovery platform and our chimeric degrader portfolio to enter the clinic”. He added, “We look forward to the clinical benefit that AC0682 treatment can potentially provide to ER-positive breast cancer patients.”
Accutar is a clinical-stage biotechnology business specializing in artificial intelligence-enabled drug discovery and its application to the discovery and development of therapeutically differentiated medications. The Phase 1 multicenter, open-label trial’s goal is to evaluate the safety, tolerability, pharmacokinetics, and initial antitumor efficacy of AC0682 therapy in patients with locally advanced or metastatic breast cancer who are ER-positive / HER2-negative. Further details about this clinical investigation are available at www.clinicaltrials.gov.
AC0682 is an orally bioavailable chimeric degrader of estrogen receptor (ER) that is being investigated for the treatment of ER-positive / human epidermal growth factor receptor 2 (HER2)-negative breast malignancies. AC0682 has shown strong and selective protein degradation of ER wildtype and mutants in preclinical tests, as well as significant anti-tumor activity in ER-positive animal tumor models, with excellent pharmacological characteristics and brain penetration. AC0682 may be a unique breast cancer therapy option due to its distinct mode of action from that of fulvestrant and newer SERDs.
